A multicenter, non-comparative, open-label extension study to assess the long term safety of Sativex oromucosal spray (Sativex; Nabiximols) as adjunctive therapy in patients with uncontrolled persistent chronic cancer related pain

Trial Profile

A multicenter, non-comparative, open-label extension study to assess the long term safety of Sativex oromucosal spray (Sativex; Nabiximols) as adjunctive therapy in patients with uncontrolled persistent chronic cancer related pain

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Registrational
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 13 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 20 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 22 Jan 2014 Planned number of patients changed from 800 to 760 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top